GRAIL, LLC Earnings Recaps
Q2 2026
Aug 7, 2026
GRAIL’s shares dropped 12.8% following earnings as investors reacted negatively to cautious outlook signals and indications of deceleration despite ongoing revenue growth in Galleri test sales.
Key takeaways
- Galleri test revenue rose 24% year-over-year in Q2 to $42.6 million, reaching over $80 million for the first half of 2026, driven by a 35% increase in test volume to 61,000 units.
- Physician adoption is increasing, supported by expansion of sales and medical teams, with positive initial feedback from new hires in the field.
- Despite strong clinical validation and recently presented data from large trials, the primary endpoint of the NHS-Galleri trial—reduction in late-stage cancers—was not met, which may weigh on investor confidence.
- GRAIL completed a $110 million financing with Samsung to support international expansion, notably in South Korea and broader Asia, aiming to diversify growth avenues.
- Management emphasized ongoing efforts toward FDA approval and reimbursement, but cautious outlook on near-term commercial ramp factors into market skepticism.
Q3 2025
Nov 13, 2025
GRAIL reported strong third-quarter performance, with a 39% increase in Gallery volume and a 29% increase in revenue year-over-year, reflecting robust uptake and strategic developments in key markets.
Key takeaways
- Gallery tests are growing in adoption, with approximately 420,000 tests sold across over 16,000 healthcare providers.
- Strategic collaboration announced with Samsung to commercialize Gallery in South Korea and other Asian markets, alongside a $110 million equity investment from Samsung.
- Successfully launched Gallery in Canada through a partnership with MedCan, expanding market presence.
- Completed a $325 million private placement to strengthen financial position as the company progresses towards key milestones.
- Positive results from PATHFINDER II study showcased substantial cancer detection improvements, underscoring Gallery’s effectiveness in early cancer diagnosis.